Clinical Trials Logo

Clinical Trial Summary

Safety and Efficacy of DFN-11 in patients with episodic migraines with or without aura.


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT02569853
Study type Interventional
Source Dr. Reddy's Laboratories Limited
Contact
Status Completed
Phase Phase 3
Start date September 21, 2015
Completion date February 26, 2018

See also
  Status Clinical Trial Phase
Recruiting NCT06047457 - A Study to Evaluate the Effectiveness and Safety of Dysport® for the Prevention of Episodic Migraine in Adults Phase 3
Completed NCT00719134 - The Effects of Expectation and Knowledge on Rizatriptan and Placebo Treatment of Acute Migraine Headache Phase 4
Completed NCT03700320 - Study to Evaluate the Safety and Tolerability of Treatment With Atogepant 60 mg Daily for the Prevention of Migraine in Participants With Episodic Migraine Phase 3
Terminated NCT04936061 - Transnasal Cooling for Migraine N/A
Recruiting NCT05042037 - Probiotics as Adjunctive Migraine Prophylaxis N/A
Recruiting NCT05281770 - Monoclonal CGRP Antibodies for Migraine Prevention - a Nationwide Real Life Study
Recruiting NCT04628429 - CGRP Inhibition, Autonomic Function, and Migraine
Active, not recruiting NCT05028569 - Study of BOTOX Injections in Prevention of Migraine in Adult Participants With Episodic Migraine Phase 3
Withdrawn NCT01257893 - Aspirin Resistance in Women With Migraine N/A
Recruiting NCT06051604 - Mi-Helper Transnasal Cooling for Acute Treatment of Migraine N/A
Completed NCT03132233 - Energy for the Brain N/A
Completed NCT03939312 - Extension Study to Evaluate the Long-Term Safety and Tolerability of Oral Atogepant for the Prevention of Migraine in Participants With Episodic Migraine Phase 3
Completed NCT03927144 - Study of Sustained Benefit of AMG334 in Adult Episodic Migraine Patients Phase 4
Recruiting NCT06248671 - Prophylactic Treatment With Atorvastatin for Episodic Migraine. Phase 2
Recruiting NCT05711394 - A Study to Assess the Adverse Events and Change in Disease Activity of Oral Atogepant Tablets in Pediatric Participants (6-17 Years of Age) With Episodic Migraine Phase 3
Recruiting NCT05449145 - The Effects of Vitamin D Plus Omega-3 Polyunsaturated Fatty Acids in Patients With Episodic Migraine N/A
Completed NCT04031781 - The Role of Left Prefrontal Transcranial Magnetic Stimulation in Episodic Migraine Prophylaxis N/A
Completed NCT05264129 - Study to Assess Adverse Events When Ubrogepant Tablets in Combination With Atogepant Tablets Are Used to Treat Adult Participants With Migraine Phase 4
Completed NCT04740827 - Atogepant for Prophylaxis of Migraine in Participants Who Failed Previous Oral Prophylactic Treatments. Phase 3
Completed NCT05853900 - Study of Two Digital Therapeutics for the Prevention of Episodic Migraine Phase 3